雷珠单抗联合或不联合维替泊芬光动力疗法治疗息肉状脉络膜血管病变的疗效与安全性:一项随机临床试验
这项双盲、多中心随机临床试验纳入322例亚洲症状性黄斑息肉状脉络膜血管病变患者,比较雷珠单抗联合维替泊芬光动力疗法与雷珠单抗单药治疗。12个月时联合治疗组最佳矫正视力平均改善8.3个字母,优于单药组的5.1个字母,且完全息肉消退率更高(69.3% vs 34.7%),注射次数更少。
要点
- 联合治疗组12个月最佳矫正视力平均改善8.3个字母,优于单药组的5.1个字母。
- 联合治疗组完全息肉消退率69.3%,高于单药组的34.7%(P < .001)。
- 12个月内联合治疗组雷珠单抗注射中位数4.0次,少于单药组的7.0次。
核心结论
- 12个月时,雷珠单抗联合维替泊芬光动力疗法在最佳矫正视力上不劣于且优于雷珠单抗单药治疗,在完全息肉消退上优于单药治疗,且所需注射次数更少。
- 作者认为,对于息肉状脉络膜血管病变患眼应考虑联合治疗。
研究设计与样本
- 双盲、多中心随机临床试验,于2013年8月7日至2017年3月2日开展。
- 纳入322例经中央阅读中心使用吲哚菁绿血管造影确诊的症状性黄斑息肉状脉络膜血管病变亚洲参与者。
- 参与者按1:1随机分配至雷珠单抗0.5 mg联合维替泊芬光动力疗法组(n = 168;联合治疗组)或雷珠单抗0.5 mg联合假光动力疗法组(n = 154;单药治疗组)。
- 所有参与者接受连续3次每月雷珠单抗注射,随后按需治疗方案;第1天接受维替泊芬光动力疗法/假光动力疗法,随后根据活动性息肉状病灶的存在按需治疗。
主要发现
- 322例参与者的基线人口学特征在治疗组间均衡;患者平均(SD)年龄68.1(8.8)岁,总体69.9%为男性。
- 基线时总体平均最佳矫正视力和平均中心子区厚度分别为61.1个字母和413.3 μm。
- 12个月时,联合治疗组较基线平均改善8.3个字母,单药治疗组改善5.1个字母(平均差异3.2个字母;95%CI,0.4-6.1),联合治疗达到预设的非劣效标准且优于单药治疗(P = .01)。
- 12个月时联合治疗组完全息肉消退率69.3%,优于单药治疗组的34.7%(P < .001)。
- 12个月内联合治疗组雷珠单抗注射中位数4.0次,单药治疗组7.0次;玻璃体出血是唯一眼部严重不良事件(联合治疗组1例[0.6%];单药治疗组3例[2.0%])。
关键数值与推荐
- 主要结局第1步评估联合治疗在最佳矫正视力较基线变化上是否非劣效于单药治疗(5个字母界值)且在完全息肉消退上优效。
- 若确立非劣效性,第2步评估联合治疗在12个月最佳矫正视力变化上是否优于单药治疗。
临床怎么用
- 作者认为,对于息肉状脉络膜血管病变患眼应考虑联合治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative age-related macular degeneration among Asian individuals. To our knowledge, there are no large randomized clinical trials to evaluate intravitreal ranibizumab, with and without verteporfin photodynamic therapy (vPDT), for the treatment of PCV. OBJECTIVE: To compare the efficacy and safety of combination therapy of ranibizumab and vPDT with ranibizumab monotherapy in PCV. DESIGN, SETTING, AND PARTICIPANTS: A double-masked, multicenter randomized clinical trial of 322 Asian participants with symptomatic macular PCV confirmed by the Central Reading Center using indocyanine green angiography was conducted between August 7, 2013, and March 2, 2017. INTERVENTIONS: Participants were randomized 1:1 to ranibizumab, 0.5 mg, and vPDT (n = 168; combination therapy group) or ranibizumab, 0.5 mg, and sham PDT (n = 154; monotherapy group). All participants received 3 consecutive monthly ranibizumab injections, followed by a pro re nata regimen. Participants also received vPDT/sham PDT on day 1, followed by a pro re nata regimen based on the presence of active polypoidal lesions. MAIN OUTCOMES AND MEASURES: Step 1 assessed whether combination therapy was noninferior (5-letter margin) to monotherapy for change in best-corrected visual acuity from baseline and superior in complete polyp regression. If noninferiority was established, step 2 assessed whether combination therapy was superior to monotherapy measured by best-corrected visual acuity change at month 12. RESULTS: Baseline demographics of the 322 participants were comparable between the treatment groups. Mean (SD) age of the patients was 68.1 (8.8) years, and overall, 69.9% of the patients were men. At baseline, the overall mean best-corrected visual acuity and mean central subfield thickness were 61.1 letters and 413.3 μm, respectively. At 12 months, mean improvement from baseline was 8.3 letters with combination therapy vs 5.1 letters with monotherapy (mean difference, 3.2 letters; 95% CI, 0.4-6.1), indicating that combination therapy met the predefined criterion for noninferiority as well as being superior to monotherapy (P = .01). Combination therapy was also superior to monotherapy in achieving complete polyp regression at month 12 (69.3% vs 34.7%; P < .001). Over 12 months, the combination therapy group received a median of 4.0 ranibizumab injections compared with 7.0 in the monotherapy group. Vitreous hemorrhage was the only ocular serious adverse event (combination therapy group, 1 [0.6%]; monotherapy group, 3 [2.0%]). CONCLUSIONS AND RELEVANCE: After 12 months, combination therapy of ranibizumab plus vPDT was not only noninferior but also superior to ranibizumab monotherapy in best-corrected visual acuity and superior in complete polyp regression while requiring fewer injections. Combination therapy should be considered for eyes with PCV. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01846273.
引用
- Koh A, Lai TYY, Takahashi K, et al. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017. PMID: 28983556. doi:10.1001/jamaophthalmol.2017.4030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。